Adherence to antiparkinson medication in a multicenter European study
Identifieur interne : 000E35 ( Istex/Corpus ); précédent : 000E34; suivant : 000E36Adherence to antiparkinson medication in a multicenter European study
Auteurs : Donald Grosset ; Angelo Antonini ; Margherita Canesi ; Gianni Pezzoli ; Andrew Lees ; Karen Shaw ; Esther Cubo ; Pablo Martinez-Martin ; Olivier Rascol ; Laurence Negre-Pages ; Ana Senard ; Johannes Schwarz ; Karl Strecker ; Heinz Reichmann ; Alexander Storch ; Matthias Löhle ; Fabrizio Stocchi ; Katherine GrossetSource :
- Movement Disorders [ 0885-3185 ] ; 2009-04-30.
English descriptors
- KwdEn :
Abstract
Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22112
Links to Exploration step
ISTEX:40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title>
<author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name>
<affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Shaw, Karen" sort="Shaw, Karen" uniqKey="Shaw K" first="Karen" last="Shaw">Karen Shaw</name>
<affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name>
<affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name>
<affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Senard, Ana" sort="Senard, Ana" uniqKey="Senard A" first="Ana" last="Senard">Ana Senard</name>
<affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name>
<affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Strecker, Karl" sort="Strecker, Karl" uniqKey="Strecker K" first="Karl" last="Strecker">Karl Strecker</name>
<affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name>
<affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name>
<affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name>
<affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><mods:affiliation>IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name>
<affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22112</idno>
<idno type="url">https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E35</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title>
<author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name>
<affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<affiliation><mods:affiliation>Parkinson Institute Milan, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Shaw, Karen" sort="Shaw, Karen" uniqKey="Shaw K" first="Karen" last="Shaw">Karen Shaw</name>
<affiliation><mods:affiliation>University College London, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name>
<affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><mods:affiliation>Carlos III Institute for Health, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Negre-Pages">Laurence Negre-Pages</name>
<affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Senard, Ana" sort="Senard, Ana" uniqKey="Senard A" first="Ana" last="Senard">Ana Senard</name>
<affiliation><mods:affiliation>Toulouse University Hospital, Toulouse, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name>
<affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Strecker, Karl" sort="Strecker, Karl" uniqKey="Strecker K" first="Karl" last="Strecker">Karl Strecker</name>
<affiliation><mods:affiliation>University of Leipzig, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Reichmann, Heinz" sort="Reichmann, Heinz" uniqKey="Reichmann H" first="Heinz" last="Reichmann">Heinz Reichmann</name>
<affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Storch, Alexander" sort="Storch, Alexander" uniqKey="Storch A" first="Alexander" last="Storch">Alexander Storch</name>
<affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lohle, Matthias" sort="Lohle, Matthias" uniqKey="Lohle M" first="Matthias" last="Löhle">Matthias Löhle</name>
<affiliation><mods:affiliation>Technical University of Dresden, Germany</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation><mods:affiliation>IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name>
<affiliation><mods:affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-04-30">2009-04-30</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="826">826</biblScope>
<biblScope unit="page" to="832">832</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</idno>
<idno type="DOI">10.1002/mds.22112</idno>
<idno type="ArticleID">MDS22112</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>therapy adherence</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<author><json:item><name>Donald Grosset MD</name>
<affiliations><json:string>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Angelo Antonini MD</name>
<affiliations><json:string>Parkinson Institute Milan, Italy</json:string>
</affiliations>
</json:item>
<json:item><name>Margherita Canesi MD</name>
<affiliations><json:string>Parkinson Institute Milan, Italy</json:string>
</affiliations>
</json:item>
<json:item><name>Gianni Pezzoli MD</name>
<affiliations><json:string>Parkinson Institute Milan, Italy</json:string>
</affiliations>
</json:item>
<json:item><name>Andrew Lees MD</name>
<affiliations><json:string>University College London, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Karen Shaw RGN</name>
<affiliations><json:string>University College London, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Esther Cubo MD</name>
<affiliations><json:string>Carlos III Institute for Health, Madrid, Spain</json:string>
</affiliations>
</json:item>
<json:item><name>Pablo Martinez‐Martin MD</name>
<affiliations><json:string>Carlos III Institute for Health, Madrid, Spain</json:string>
</affiliations>
</json:item>
<json:item><name>Olivier Rascol MD</name>
<affiliations><json:string>Toulouse University Hospital, Toulouse, France</json:string>
</affiliations>
</json:item>
<json:item><name>Laurence Negre‐Pages MD</name>
<affiliations><json:string>Toulouse University Hospital, Toulouse, France</json:string>
</affiliations>
</json:item>
<json:item><name>Ana Senard MD</name>
<affiliations><json:string>Toulouse University Hospital, Toulouse, France</json:string>
</affiliations>
</json:item>
<json:item><name>Johannes Schwarz MD</name>
<affiliations><json:string>University of Leipzig, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>Karl Strecker MD</name>
<affiliations><json:string>University of Leipzig, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>Heinz Reichmann MD</name>
<affiliations><json:string>Technical University of Dresden, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>Alexander Storch MD</name>
<affiliations><json:string>Technical University of Dresden, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>Matthias Löhle MD</name>
<affiliations><json:string>Technical University of Dresden, Germany</json:string>
</affiliations>
</json:item>
<json:item><name>Fabrizio Stocchi MD</name>
<affiliations><json:string>IRCCS San Raffaele Pisana, Rome, Italy</json:string>
</affiliations>
</json:item>
<json:item><name>Katherine Grosset MD</name>
<affiliations><json:string>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>Parkinson's disease</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>therapy adherence</value>
</json:item>
</subject>
<language><json:string>eng</json:string>
</language>
<abstract>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P > 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</abstract>
<qualityIndicators><score>6.754</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>612 x 810 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>1812</abstractCharCount>
<pdfWordCount>3754</pdfWordCount>
<pdfCharCount>25613</pdfCharCount>
<pdfPageCount>7</pdfPageCount>
<abstractWordCount>262</abstractWordCount>
</qualityIndicators>
<title>Adherence to antiparkinson medication in a multicenter European study</title>
<genre><json:string>Serial article</json:string>
</genre>
<host><volume>24</volume>
<pages><total>7</total>
<last>832</last>
<first>826</first>
</pages>
<issn><json:string>0885-3185</json:string>
</issn>
<issue>6</issue>
<subject><json:item><value>Research Article</value>
</json:item>
</subject>
<genre></genre>
<language><json:string>unknown</json:string>
</language>
<title>Movement Disorders</title>
<doi><json:string>10.1002/(ISSN)1531-8257</json:string>
</doi>
</host>
<publicationDate>2009</publicationDate>
<copyrightDate>2009</copyrightDate>
<doi><json:string>10.1002/mds.22112</json:string>
</doi>
<id>40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</id>
<fulltext><json:item><original>true</original>
<mimetype>application/pdf</mimetype>
<extension>pdf</extension>
<uri>https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/pdf</uri>
</json:item>
<json:item><original>false</original>
<mimetype>application/zip</mimetype>
<extension>zip</extension>
<uri>https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability><p>Wiley Subscription Services, Inc., A Wiley Company</p>
</availability>
<date>2009</date>
</publicationStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title>
<author><persName><forename type="first">Donald</forename>
<surname>Grosset</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation>
</author>
<author><persName><forename type="first">Angelo</forename>
<surname>Antonini</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Parkinson Institute Milan, Italy</affiliation>
</author>
<author><persName><forename type="first">Margherita</forename>
<surname>Canesi</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Parkinson Institute Milan, Italy</affiliation>
</author>
<author><persName><forename type="first">Gianni</forename>
<surname>Pezzoli</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Parkinson Institute Milan, Italy</affiliation>
</author>
<author><persName><forename type="first">Andrew</forename>
<surname>Lees</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>University College London, United Kingdom</affiliation>
</author>
<author><persName><forename type="first">Karen</forename>
<surname>Shaw</surname>
<roleName type="degree">RGN</roleName>
</persName>
<affiliation>University College London, United Kingdom</affiliation>
</author>
<author><persName><forename type="first">Esther</forename>
<surname>Cubo</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation>
</author>
<author><persName><forename type="first">Pablo</forename>
<surname>Martinez‐Martin</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation>
</author>
<author><persName><forename type="first">Olivier</forename>
<surname>Rascol</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Toulouse University Hospital, Toulouse, France</affiliation>
</author>
<author><persName><forename type="first">Laurence</forename>
<surname>Negre‐Pages</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Toulouse University Hospital, Toulouse, France</affiliation>
</author>
<author><persName><forename type="first">Ana</forename>
<surname>Senard</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Toulouse University Hospital, Toulouse, France</affiliation>
</author>
<author><persName><forename type="first">Johannes</forename>
<surname>Schwarz</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>University of Leipzig, Germany</affiliation>
</author>
<author><persName><forename type="first">Karl</forename>
<surname>Strecker</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>University of Leipzig, Germany</affiliation>
</author>
<author><persName><forename type="first">Heinz</forename>
<surname>Reichmann</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Technical University of Dresden, Germany</affiliation>
</author>
<author><persName><forename type="first">Alexander</forename>
<surname>Storch</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Technical University of Dresden, Germany</affiliation>
</author>
<author><persName><forename type="first">Matthias</forename>
<surname>Löhle</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>Technical University of Dresden, Germany</affiliation>
</author>
<author><persName><forename type="first">Fabrizio</forename>
<surname>Stocchi</surname>
<roleName type="degree">MD</roleName>
</persName>
<affiliation>IRCCS San Raffaele Pisana, Rome, Italy</affiliation>
</author>
<author><persName><forename type="first">Katherine</forename>
<surname>Grosset</surname>
<roleName type="degree">MD</roleName>
</persName>
<note type="correspondence"><p>Correspondence: Southern General Hospital, Glasgow, United Kingdom</p>
</note>
<affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation>
</author>
</analytic>
<monogr><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="pISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<idno type="DOI">10.1002/(ISSN)1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-04-30"></date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="826">826</biblScope>
<biblScope unit="page" to="832">832</biblScope>
</imprint>
</monogr>
<idno type="istex">40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</idno>
<idno type="DOI">10.1002/mds.22112</idno>
<idno type="ArticleID">MDS22112</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>2009</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head>
<item><term>Parkinson's disease</term>
</item>
<item><term>therapy adherence</term>
</item>
</list>
</keywords>
</textClass>
<textClass><keywords scheme="Journal Subject"><list><head>Article category</head>
<item><term>Research Article</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="2008-01-28">Received</change>
<change when="2008-04-05">Registration</change>
<change when="2009-04-30">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><original>false</original>
<mimetype>text/plain</mimetype>
<extension>txt</extension>
<uri>https://api.istex.fr/document/40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1531-8257</doi>
<issn type="print">0885-3185</issn>
<issn type="electronic">1531-8257</issn>
<idGroup><id type="product" value="MDS"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title>
<title type="subtitle">Official Journal of the Movement Disorder Society</title>
<title type="short">Mov. Disord.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v24:6</doi>
<numberingGroup><numbering type="journalVolume" number="24">24</numbering>
<numbering type="journalIssue">6</numbering>
</numberingGroup>
<coverDate startDate="2009-04-30">30 April 2009</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="50" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22112</doi>
<idGroup><id type="unit" value="MDS22112"></id>
</idGroup>
<countGroup><count type="pageTotal" number="7"></count>
</countGroup>
<titleGroup><title type="articleCategory">Research Article</title>
<title type="tocHeading1">Research Articles</title>
</titleGroup>
<copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright>
<eventGroup><event type="manuscriptReceived" date="2008-01-28"></event>
<event type="manuscriptRevised" date="2008-04-02"></event>
<event type="manuscriptAccepted" date="2008-04-05"></event>
<event type="publishedOnlineEarlyUnpaginated" date="2009-02-03"></event>
<event type="firstOnline" date="2009-02-03"></event>
<event type="publishedOnlineFinalForm" date="2009-04-24"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-20"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">826</numbering>
<numbering type="pageLast">832</numbering>
</numberingGroup>
<correspondenceTo>Southern General Hospital, Glasgow, United Kingdom</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22112.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="3"></count>
<count type="tableTotal" number="3"></count>
<count type="referenceTotal" number="20"></count>
<count type="wordTotal" number="5265"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Adherence to antiparkinson medication in a multicenter European study</title>
<title type="short" xml:lang="en">Adherence to Antiparkinson Medication</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Donald</givenNames>
<familyName>Grosset</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Angelo</givenNames>
<familyName>Antonini</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Margherita</givenNames>
<familyName>Canesi</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Gianni</givenNames>
<familyName>Pezzoli</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Andrew</givenNames>
<familyName>Lees</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Karen</givenNames>
<familyName>Shaw</familyName>
<degrees>RGN</degrees>
</personName>
</creator>
<creator xml:id="au7" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Esther</givenNames>
<familyName>Cubo</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au8" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Pablo</givenNames>
<familyName>Martinez‐Martin</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au9" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Olivier</givenNames>
<familyName>Rascol</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au10" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Laurence</givenNames>
<familyName>Negre‐Pages</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au11" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Ana</givenNames>
<familyName>Senard</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au12" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Johannes</givenNames>
<familyName>Schwarz</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au13" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Karl</givenNames>
<familyName>Strecker</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au14" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Heinz</givenNames>
<familyName>Reichmann</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au15" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Alexander</givenNames>
<familyName>Storch</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au16" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Matthias</givenNames>
<familyName>Löhle</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au17" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Fabrizio</givenNames>
<familyName>Stocchi</familyName>
<degrees>MD</degrees>
</personName>
</creator>
<creator xml:id="au18" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Katherine</givenNames>
<familyName>Grosset</familyName>
<degrees>MD</degrees>
</personName>
<contactDetails><email>kgrosset@nhs.net</email>
</contactDetails>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Parkinson Institute Milan, Italy</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>University College London, United Kingdom</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="ES" type="organization"><unparsedAffiliation>Carlos III Institute for Health, Madrid, Spain</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Toulouse University Hospital, Toulouse, France</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af6" countryCode="DE" type="organization"><unparsedAffiliation>University of Leipzig, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af7" countryCode="DE" type="organization"><unparsedAffiliation>Technical University of Dresden, Germany</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af8" countryCode="IT" type="organization"><unparsedAffiliation>IRCCS San Raffaele Pisana, Rome, Italy</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword>
<keyword xml:id="kwd2">therapy adherence</keyword>
</keywordGroup>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (<i>P</i>
= NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (<i>P</i>
= 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), <i>P</i>
= 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (<i>P</i>
< 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Adherence to antiparkinson medication in a multicenter European study</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>Adherence to Antiparkinson Medication</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Adherence to antiparkinson medication in a multicenter European study</title>
</titleInfo>
<name type="personal"><namePart type="given">Donald</namePart>
<namePart type="family">Grosset</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Angelo</namePart>
<namePart type="family">Antonini</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Parkinson Institute Milan, Italy</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Margherita</namePart>
<namePart type="family">Canesi</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Parkinson Institute Milan, Italy</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Gianni</namePart>
<namePart type="family">Pezzoli</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Parkinson Institute Milan, Italy</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Andrew</namePart>
<namePart type="family">Lees</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>University College London, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Karen</namePart>
<namePart type="family">Shaw</namePart>
<namePart type="termsOfAddress">RGN</namePart>
<affiliation>University College London, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Esther</namePart>
<namePart type="family">Cubo</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Pablo</namePart>
<namePart type="family">Martinez‐Martin</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Carlos III Institute for Health, Madrid, Spain</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Olivier</namePart>
<namePart type="family">Rascol</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Toulouse University Hospital, Toulouse, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Laurence</namePart>
<namePart type="family">Negre‐Pages</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Toulouse University Hospital, Toulouse, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Ana</namePart>
<namePart type="family">Senard</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Toulouse University Hospital, Toulouse, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Johannes</namePart>
<namePart type="family">Schwarz</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>University of Leipzig, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Karl</namePart>
<namePart type="family">Strecker</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>University of Leipzig, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Heinz</namePart>
<namePart type="family">Reichmann</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Technical University of Dresden, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Alexander</namePart>
<namePart type="family">Storch</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Technical University of Dresden, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Matthias</namePart>
<namePart type="family">Löhle</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Technical University of Dresden, Germany</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Fabrizio</namePart>
<namePart type="family">Stocchi</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>IRCCS San Raffaele Pisana, Rome, Italy</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Katherine</namePart>
<namePart type="family">Grosset</namePart>
<namePart type="termsOfAddress">MD</namePart>
<affiliation>Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom</affiliation>
<description>Correspondence: Southern General Hospital, Glasgow, United Kingdom</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="originalCategForm">article</genre>
<originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place><placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2009-04-30</dateIssued>
<dateCaptured encoding="w3cdtf">2008-01-28</dateCaptured>
<dateValid encoding="w3cdtf">2008-04-05</dateValid>
<copyrightDate encoding="w3cdtf">2009</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="figures">3</extent>
<extent unit="tables">3</extent>
<extent unit="references">20</extent>
<extent unit="words">5265</extent>
</physicalDescription>
<abstract lang="en">Two small studies reported suboptimal therapy adherence in Parkinson's disease. We conducted a larger multicenter European study to assess medicine‐taking behavior. Parkinson's disease patients taking dopaminergic therapy were enrolled in 8 centers in 5 countries, and disease severity and demographics recorded. Antiparkinson drug adherence was measured for 4 weeks using electronic monitoring bottles which record the date and time of cap opening (Aardex®, Switzerland). One hundred twelve patients, mean age 65 years (standard deviation (SD) 10), with Parkinson's disease for 7.7 (SD 8.2) years completed the study. Total median adherence (doses taken/doses prescribed) was 97.7% (interquartile range [IQ] 90.6–100), days adherence (correct dose days) was 86.2% (IQ 61.1–96.2) and timing adherence (doses taken at correct time intervals) was 24.4% (IQ 5.3–56.5). Fourteen patients (12.5%) took less than 80% of prescribed doses, which was defined as suboptimal adherence. Patients with satisfactory adherence took a median of 8 mg/day (IQ 0–33) less than their prescribed dose of levodopa (P = NS), while suboptimal adherence patients took a median of 481 mg/day (IQ 205–670) less than their prescribed dose (P = 0.0006). The Parkinson motor score was significantly higher in patients with suboptimal adherence at 29 (IQ 20–40), versus those with satisfactory adherence at 19 (IQ 13–26), P = 0.005. Once daily drugs had significantly better adherence when compared with drugs prescribed more frequently (P < 0.0001). Suboptimal therapy adherence is associated with significant deviation from prescribed levodopa doses, despite greater Parkinson's motor severity. Optimizing oral medication intake has a potential role in maximizing the therapy response in Parkinson's disease. © 2009 Movement Disorder Society</abstract>
<subject lang="en"><genre>Keywords</genre>
<topic>Parkinson's disease</topic>
<topic>therapy adherence</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Movement Disorders</title>
<subTitle>Official Journal of the Movement Disorder Society</subTitle>
</titleInfo>
<titleInfo type="abbreviated"><title>Mov. Disord.</title>
</titleInfo>
<subject><genre>article category</genre>
<topic>Research Article</topic>
</subject>
<identifier type="ISSN">0885-3185</identifier>
<identifier type="eISSN">1531-8257</identifier>
<identifier type="DOI">10.1002/(ISSN)1531-8257</identifier>
<identifier type="PublisherID">MDS</identifier>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>24</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>6</number>
</detail>
<extent unit="pages"><start>826</start>
<end>832</end>
<total>7</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7</identifier>
<identifier type="DOI">10.1002/mds.22112</identifier>
<identifier type="ArticleID">MDS22112</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition>
<recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
<recordContentSource>WILEY</recordContentSource>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:40F6147EA45E323B9E9D2F80F0E5F179BA4C28F7 |texte= Adherence to antiparkinson medication in a multicenter European study }}
This area was generated with Dilib version V0.6.23. |